RxDoctor Payments Data

Melody Denson, MD

Urology · Austin, TXNPI 1154394997

Payments from drug & device makers

$35,642in general payments, 2019–2025

Across 796 payments — averaging $44.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$13K
  • Medtronic$7K
  • Boston Scientific$5K
  • AbbVie$2K
  • Sumitomo Pharma America, Inc.$2K
  • Coloplast$1K
  • plus $5K from 48 others

What the payments were for

  • Consulting fees$2,6637%
  • Speaking & faculty fees$16,27546%
  • Travel & lodging$2,3146%
  • Food & beverage$13,98239%
  • Education$4071%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,642 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$504,511
Medicare patients
1,055
Services billed
22,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron765$629,284
MyrbetriqMirabegron618$470,594
Mirabegron ErMirabegron195$104,717
ElmironPentosan Polysulfate Sodium24$36,830
Estradiol494$23,764
NitrofurantoinNitrofurantoin Macrocrystal354$13,929
Trimethoprim151$10,542
Fosfomycin Tromethamine30$9,524
PremarinEstrogens, Conjugated21$9,009
ProgesteroneProgesterone, Micronized179$8,148
Methenamine Hippurate119$8,107
Oxybutynin Chloride ErOxybutynin Chloride386$7,901
OsphenaOspemifene19$7,822
Cephalexin397$7,140
Tamsulosin Hcl340$5,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,877$629,284765 claims
Astellas Pharma US IncMyrbetriq$13,236$470,594618 claims
PfizerPremarin$444$9,00921 claims
Duchesnay USA IncorporatedOsphena$26$7,82219 claims
AMAG Pharmaceuticals, Inc.Intrarosa$138$3,89416 claims
AbbVieArmour Thyroid$1,903$1,44214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →